Skip to main content
  • One-year Outcome of Magnetic Resonance-guided Stereotactic Laser Amygdalohippocampotomy for Mesial Temporal Lobe Epilepsy

    Final Number:

    Matthew A. Stern BS; Jon T. Willie MD, PhD; Robert E. Gross MD, PhD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: 2016 ASSFN Biennial Meeting Late Breaking

    Introduction: Stereotactic magnetic resonance imaging-guided laser amygdalohippocampotomy (SLAH) is a minimally invasive approach to surgical treatment of drug-resistant mesial temporal lobe epilepsy (MTLE). Although short term outcomes in two small series have been reported (Willie et al., 2014; Kang et al., 2016), one year outcomes represent the gold standard by which to compare SLAH to standard open temporal surgery such as anterior temporal lobectomy (ATL) or selective amygdalohippocampectomy (SAH), a recent meta-analysis of which demonstrated one-year seizure freedom rates of 75% and 67%, respectively. The subset with mesial temporal sclerosis (MTS) yielded higher rates (78% verses 71%, respectively). Here we present a consecutive series of 41 patients with MTLE that underwent SLAH.

    Methods: All 41 patients with MTLE (25 of whom had MTS) who underwent SLAH at our institution and who had follow-up =12 months were included. Surgical outcome was stratified by Engel's classification (class 1 = free of disabling seizures). Results were retrospectively analyzed as a non-inferiority trial with the objective performance criterion (OPC) = 67% (equivalent to SAH), and the non-inferiority margin (f) = 8% (= absolute risk reduction between ATLAH and SAH). The subgroups with and without MTS were similarly analyzed (OPC=71%, f=7%).

    Results: At one-year following SLAH 56.1% (95% CI ±15.2%) of all MTLE patients and 64.0% (95% CI ±18.8%) of MTS patients were free of disabling seizures (Engel 1) suggesting statistical non-inferiority to SAH. Fewer (43.8%, CI 95% ±24.3%) of non-MTS patients were seizure-free.

    Conclusions: In this largest single center experience to date, SLAH was non-inferior to SAH at one year, with superior results in patients with MTS. Compared to open temporal lobe surgery, SLAH is an effective minimally invasive alternative with a favorable neurocognitive profile. In the minority of patients that do not achieve seizure freedom, SLAH presents no barrier to additional open surgery.

    Patient Care: Minimize cognitive impact and surgical complications from standard surgery for mesial temporal lobe epilepsy

    Learning Objectives: Understand the outcome of stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy as compared to standard open resection surgery.

    References: 1: Willie JT, Laxpati NG, Drane DL, Gowda A, Appin C, Hao C, Brat DJ, Helmers SL, Saindane A, Nour SG, Gross RE. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery. 2014 Jun;74(6):569-84; discussion 584-5. doi: 10.1227/NEU.0000000000000343. PubMed PMID: 24618797; PubMed Central PMCID: PMC4151501. 2: Kang JY, Wu C, Tracy J, Lorenzo M, Evans J, Nei M, Skidmore C, Mintzer S, Sharan AD, Sperling MR. Laser interstitial thermal therapy for medically intractable mesial temporal lobe epilepsy. Epilepsia. 2016 Feb;57(2):325-34. doi: 10.1111/epi.13284. Epub 2015 Dec 24. PubMed PMID: 26697969.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy